Enveric

  NAPLES, Fla., Oct. 7, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and…

– Paving the way to select lead drug candidates for preclinical studies to support clinical evaluation in cancer-related distress – NAPLES, Fla., Oct. 5, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),…

  NAPLES, Fla., Sept. 20, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform for the mind and body…

Enveric intends to immediately accelerate the development of a novel Psychedelic molecule for Cancer Related Distress   NAPLES, Fla., Sept. 17, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology…

  NAPLES, Fla., Sept. 9, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that…

Company has also released its second quarter and first half financial results for the period ended June 30, 2021 NAPLES, Fla., Aug. 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a…

Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval NAPLES, Fla., July 8, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing…